Ceftobiprole medocaril sodium CAS# 252188-71-9 头孢比罗酯钠

Ceftobiprole medocaril (BAL5788) is a fifth-generation cephalosporin prodrug that exhibits potent in vitro and in vivo antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative pathogens. In vitro studies have demonstrated its efficacy against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to daptomycin, linezolid, or vancomycin, as well as Streptococcus pneumoniae, Enterococcus faecalis, and various Enterobacteriaceae. In animal models, ceftobiprole medocaril has shown significant therapeutic activity. For instance, in a murine urinary tract infection model, it was equally effective against both β-lactamase-producing and non-producing Enterococcus faecalis strains, outperforming ampicillin in β-lactamase-producing strains . Additionally, in a murine thigh infection model, it effectively reduced tissue bacterial counts of MRSA, demonstrating its potential for treating deep-seated infections.